Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain

doi:10.1016/0306-4522(94)00527-C

Neuroscience

Volume 65, Issue 3, April 1995, Pages 731-745

https://doi.org/10.1016/0306-4522(94)00527-C Get rights and content

Abstract

We have established the cellular distribution of the dopamine D₃ receptor using tritiated 7-hydroxy-N-N-di-n-propyl-2-aminotetralin and a complementary RNA probe to visualize autoradiographically the protein in binding studies and the gene transcripts byin situ hybridization, respectively. Studies with these two markers confirm the restricted expression of the D₃ receptor in few brain areas, i.e. mainly the ventral striatal complex, the substantia nigra-ventral tegmental area and the cerebellum. In nucleus accumbens, the D₃ receptor was mainly expressed in medium-sized neurons of the rostral pole and ventromedial shell subdivisions, but not of the core or septal pole, i.e. accumbal subdivisions expressing the D₂ receptor. In the ventromedial shell, about 60% of the D₃ receptor-expressing neurons were neurotensin neurons, presumably projecting to the ventral pallidum. In the islands of Calleja, both D₃ receptor binding and messenger RNA were abundant in the entire population of granule cells. These cells are known to make sparse contacts with dopaminergic axons and also to express the D₁ receptor. In the mesencephalon, low levels of D₃ messenger RNA were detected in few dopamine neurons of substantia nigra pars lateralis and ventral tegmental area. In addition, some D₃ receptor binding but not messenger RNA was detected in medial substantia nigra and lateral ventral tegmental area, where the receptor is presumably located presynaptically on afferents. In the archicerebellum, Purkinje cell perikarya in lobules 9 and 10 expressed the D₃ receptor messenger RNA, whereas binding sites were found in the molecular layer, where corresponding dendrites but no known dopaminergic projection from mesencephalon are found.

The occurrence of D₃ receptor gene expression in some brain areas receiving low dopamine innervation supports the hypothesis that this receptor may mediate non-synaptic actions of dopamine.

References (66)

BecksteadR.M. et al.
Efferent connections of the substantia nigra and ventral tegmental area in rat brain
Brain Res.
(1979)
BouthenetM.L. et al.
A detailed mapping of dopamine D-2 receptors in rat central nervous system by autoradiography with [¹²⁵I]iodosulpride
Neuroscience
(1987)
BouthenetM.L. et al.
Localization of dopamine D₃ receptor mRNA in the rat brain usingin situ hybridization histochemistry: comparison with dopamine D₂ receptor mRNA
Brain Res.
(1991)
CampbellK.J. et al.
Co-localization of tyrosine hydroxylase and glutamate decar☐ylase in a subpopulation of single nigrotectal projections neurons
Brain Res.
(1991)
ChomczynskiP. et al.
Single-step method of RNA isolation by acid guanidiuium thiocyanate-chloroform extraction
Analyt. Biochem.
(1987)
GirosB. et al.
Cloning and functional characterization of a cocaine-sensitive dopamine transporter
Fedn. Eur. biochem. Socs Lett.
(1991)
HessE.J. et al.
Tottering and leaner mutations perturb transient developmental expression of tyrosine hydroxylase in embryologically distinct Purkinje cells
Neuron
(1991)
HolzmanP.S.
Behavioral markers of schizophrenia useful for genetic studies
J. psychiat. Res.
(1992)
IkaiY. et al.
Dopaminergic and non-dopaminergic neurons in the ventral tegmental area of the rat project, respectively, to the cerebellar cortex and deep cerebellar nuclei
Neuroscience
(1992)
KislauskisE. et al.
The rat gene encoding neurotensin and neuromedin N
J. biol. Chem.
(1988)

KizerJ.S. et al.

The projections of the A8, A9 and A10 dopaminergic cell bodies: evidence for a nigral-hypothalamic-median eminence dopaminergic pathway

Brain Res.

(1976)

MansourA. et al.

A comparison of D₁ receptor binding and mRNA in rat brain using receptor autoradiographic andin situ hybridization techniques

Neuroscience

(1992)

MarshallJ.F. et al.

Dopamine high-affinity transport site topography in rat brain: major differences between dorsal and ventral striatum

Neuroscience

(1990)

MellerE. et al.

Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D₃ receptors

Eur. J. Pharmac.

(1993)

MeredithG.E. et al.

Morphological differences between projection neurons of the core and shell in the nucleus accumbens of the rat

Neuroscience

(1992)

MoriizumiT. et al.

Separate neuronal populations of the cat substantia nigra pars lateralis with distinct projection sites and transmitter phenotypes

Neuroscience

(1992)

SchwartzJ.-C. et al.

The dopamine receptor family: molecular biology and pharmacology

Sem. Neurosci.

(1992)

SokoloffP. et al.

Pharmacology of human D₃ dopamine receptor expressed in a mammalian cell line: comparison with D₂ receptor

Eur. J. Pharmac. molec. Pharmac. Sect.

(1992)

SwansonL.W.

The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat

Brain Res. Bull.

(1982)

TakadaM. et al.

Tyrosine hydroxylase immunoreactivity in cerebellar Purkinje cells of the rat

Neurosci. Lett.

(1993)

TokunagaA. et al.

Nigral projections to the quadrigeminal body and the rat, retrograde horseradish peroxidase and fluorescent double labeling studies

J. Neurosci. Res.

(1984)

ZahmD.S. et al.

On the significance of subterritories in the “accumbens” part of the rat ventral striatum

Neuroscience

(1992)

BerthieB. et al.

A small population of Purkinje cells in the posterior vermis is specifically labeled by a tyrosine hydroxylase antibody

BjörklundA. et al.

Dopamine-containing systems in the CNS

BrogJ.S. et al.

The patterns of afferent innervation of the core and shell in the “accumbens” part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold

J. comp. Neurol.

(1993)

CarlssonA.

The current status of the dopamine hypothesis of schizophrenia

Neuropsychopharmacology

(1988)

CivelliO. et al.

Molecular diversity of dopamine receptors

A. Rev. Pharmac. Toxic.

(1993)

ClementzB.A. et al.

Is eye movement dysfunction a biological marker for schizophrenia? A methodological review

Psychol. Bull.

(1990)

CoonH. et al.

Linkage analysis of schizophrenia with gene dopamine receptor genes in nine pedigrees

Am. J. hum. Genet.

(1993)

CrocqM.A. et al.

Association between schizophrenia and homozygosity at the dopamine D₃ receptor gene

J. med. Genet.

(1992)

DeutchA.Y.

Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease

J. neural Transm. (Gen. Sect.)

(1993)

DiazJ. et al.

Opposing roles for dopamine D₂ and D₃ receptors on neurotensin mRNA expression in nucleus accumbens

Eur. J. Neurosci.

(1994)

FallonJ.H. et al.

Substantia nigra

Cited by (328)

The histamine H3 receptor modulates dopamine D2 receptor–dependent signaling pathways and mouse behaviors
2023, Journal of Biological Chemistry
The histamine H3 receptor (H3R) is highly enriched in the spiny projection neurons (SPNs) of the striatum, in both the D1 receptor (D1R)–expressing and D2 receptor (D2R)–expressing populations. A crossantagonistic interaction between H3R and D1R has been demonstrated in mice, both at the behavioral level and at the biochemical level. Although interactive behavioral effects have been described upon coactivation of H3R and D2R, the molecular mechanisms underlying this interaction are poorly understood. Here, we show that activation of H3R with the selective agonist R-(−)-α-methylhistamine dihydrobromide mitigates D2R agonist–induced locomotor activity and stereotypic behavior. Using biochemical approaches and the proximity ligation assay, we demonstrated the existence of an H3R–D2R complex in the mouse striatum. In addition, we examined consequences of simultaneous H3R–D2R agonism on the phosphorylation levels of several signaling molecules using immunohistochemistry. H3R agonist treatment modulated Akt (serine/threonine PKB)–glycogen synthase kinase 3 beta signaling in response to D2R activation via a β-arrestin 2–dependent mechanism in D2R-SPNs but not in D1R-SPNs. Phosphorylation of mitogen- and stress-activated protein kinase 1 and rpS6 (ribosomal protein S6) was largely unchanged under these conditions. As Akt–glycogen synthase kinase 3 beta signaling has been implicated in several neuropsychiatric disorders, this work may help clarify the role of H3R in modulating D2R function, leading to a better understanding of pathophysiology involving the interaction between histamine and dopamine systems.
Central nervous system interaction and crosstalk between nAChRs and other ionotropic and metabotropic neurotransmitter receptors
2023, Pharmacological Research
Neuronal nicotinic acetylcholine receptors (nAChRs) are widely distributed in both the peripheral and the central nervous systems. nAChRs exert a crucial modulatory influence on several brain biological processes; they are involved in a variety of neuronal diseases including Parkinson’s disease, Alzheimer’s disease, epilepsy, and nicotine addiction. The influence of nAChRs on brain function depends on the activity of other neurotransmitter receptors that co-exist with nAChRs on neurons. In fact, the crosstalk between receptors is an important mechanism of neurotransmission modulation and plasticity. This may be due to converging intracellular pathways but also occurs at the membrane level, because of direct physical interactions between receptors. In this line, this review is dedicated to summarizing how nAChRs and other ionotropic and metabotropic receptors interact and the relevance of nAChRs cross-talks in modulating various neuronal processes ranging from the classical modulation of neurotransmitter release to neuron plasticity and neuroprotection.
G-protein biased signaling agonists of Dopamine D3 receptor promote distinct activation patterns of ERK1/2
2022, Pharmacological Research
Dopamine D3 receptors (D3R) have a causal role in neurological and psychiatric disorders. We have developed a novel class of G-protein biased (GPB) signaling D3R agonists with minimal β-arrestin2 (βarr2) recruitment and demonstrated efficacy in rodent model of Parkinson’s disease. This contrasts with unbiased (UB) D3R agonists like Pramipexole which recruit both β-arrestin and G-proteins for signaling. In this study, we investigated the effects of GPB and UB agonists on D3R mediated activation of mono and dual phosphorylation of ERK1/2. We used the neuronal-like SH-SY5Y cells stably expressing D3R and βarr2 knockdown (βarr2KD) to delineate the roles of G_i/o and βarr2 on phosphorylation patterns of ERK1/2 induced by D3R agonists. Results indicate GPB and UB agonists promote similar early and late phase mono activation patterns of ERK1/2. On the contrary, GPB and UB agonists promote either early or early and late phase dual activation of ERK1/2, respectively. The early phase dual activation of ERK1/2 is predominantly promoted by G_i/o while the late phase dual activation by βarr2 recruitment. PKC plays a significant role in both the early and late phase dual phosphorylation of ERK1/2. βarr2KD significantly increased short- and long-term dual phosphorylation levels of ERK1/2 induced by GPB agonists which was inhibited by a combination of G_i/o and PKC inhibitors. Interestingly, βarr2KD significantly reduced the short and long-term dual phosphorylation of ERK1/2 by UB agonists. Overall, this study highlights that biased signaling agonists of D3R have differential effects on ERK1/2 which may be advantageous to develop better drugs.
Topiramate-chitosan nanoparticles prevent morphine reinstatement with no memory impairment: Dopaminergic and glutamatergic molecular aspects in rats
2021, Neurochemistry International
Citation Excerpt :
On the other hand, our findings showed no changes in the D3R in the dorsal hippocampus in morphine-exposed animals and subsequently to both TPM–CS–NP and S-TPM treatments. According to literature data, D3R are restricted to mesolimbic brain areas, including NAc (Diaz et al., 1994). Concentration of DA in the synaptic cleft is the primary determinant of DA signaling intensity.
Besides their clinical application, chronic misuse of opioids has often been associated to drug addiction due to their addictive properties, underlying neuroadaptations of AMPA glutamate-receptor-dependent synaptic plasticity. Topiramate (TPM), an AMPAR antagonist, has been used to treat psychostimulants addiction, despite its harmful effects on memory. This study aimed to evaluate the effects of a novel topiramate nanosystem on molecular changes related to morphine reinstatement. Rats were previously exposed to morphine in conditioned place preference (CPP) paradigm and treated with topiramate-chitosan nanoparticles (TPM–CS–NP) or non-encapsulated topiramate in solution (S-TPM) during CPP extinction; following memory performance evaluation, they were re-exposed to morphine reinstatement. While morphine-CPP extinction was comparable among all experimental groups, TPM–CS–NP treatment prevented morphine reinstatement, preserving memory performance, which was impaired by both morphine-conditioning and S-TPM treatment. In the NAc, morphine increased D1R, D2R, D3R, DAT, GluA1 and MOR immunoreactivity. It also increased D1R, DAT, GluA1 and MOR in the dorsal hippocampus. TPM–CS–NP treatment decreased D1R, D3R and GluA1 and increased DAT in the NAc, decreasing GluA1 and increasing D2 and DAT in the dorsal hippocampus. Taken together, we may infer that TPM–CS–NP treatment was able to prevent the morphine reinstatement without memory impairment. Therefore, TPM–CS–NP may be considered an innovative therapeutic tool due to its property to prevent opioid reinstatement because it acts modifying both dopaminergic and glutamatergic neurotransmission, which are commonly related to morphine addiction.
Akathisia and Restless Legs Syndrome: Solving the Dopaminergic Paradox
2021, Sleep Medicine Clinics
The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease
2020, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Addictions involve a spectrum of behaviors that encompass features of impulsivity and compulsivity, herein referred to as impulsive-compulsive spectrum disorders (ICSDs). The etiology of ICSDs likely involves a complex interplay among neurobiological, psychological and social risk factors. Neurobiological risk factors include the status of the neuroanatomical circuits that govern ICSDs. These circuits can be altered by disease, as well as exogenous influences such as centrally-acting pharmacologics. The ‘poster child’ for this scenario is Parkinson’s disease (PD) medically managed by pharmacological treatments. PD is a progressive neurodegenerative disease that involves a gradual loss of dopaminergic neurons largely within nigrostriatal projections. Replacement therapy includes dopamine receptor agonists that directly activate postsynaptic dopamine receptors (bypassing the requirement for functioning presynaptic terminals). Some clinically useful dopamine agonists, e.g., pramipexole and ropinirole, exhibit high affinity for the D2/D3 receptor subtypes. These agonists provide excellent relief from PD motor symptoms, but some patients exhibit debilitating ICSD. Teasing out the neuropsychiatric contribution of PD-associated pathology from the drugs used to treat PD motor symptoms is challenging. In this review, we posit that modern clinical and preclinical research converge on the conclusion that dopamine replacement therapy can mediate addictions in PD and other neurological disorders. We provide five categories of evidences that align with this position: (i) ICSD prevalence is greater with D2/D3 receptor agonist therapy vs PD alone. (ii) Capacity of dopamine replacement therapy to produce addiction-like behaviors is independent of disease for which the therapy is being provided. (iii) ICSD-like behaviors are recapitulated in laboratory rats with and without PD-like pathology. (iv) Behavioral pathology co-varies with drug exposure. (v) ICSD Features of ICSDs are consistent with agonist pharmacology and neuroanatomical substrates of addictions. Considering the underpinnings of ICSDs in PD should not only help therapeutic decision-making in neurological disorders, but also apprise ICSDs in general.

View all citing articles on Scopus

View full text

Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain

Abstract

Brain Res.

Neuroscience

Brain Res.

Brain Res.

Analyt. Biochem.

Fedn. Eur. biochem. Socs Lett.

Neuron

J. psychiat. Res.

Neuroscience

J. biol. Chem.

Brain Res.

Neuroscience

Neuroscience

Eur. J. Pharmac.

Neuroscience

Neuroscience

Sem. Neurosci.

Eur. J. Pharmac. molec. Pharmac. Sect.

Brain Res. Bull.

Neurosci. Lett.

J. Neurosci. Res.

Neuroscience

A small population of Purkinje cells in the posterior vermis is specifically labeled by a tyrosine hydroxylase antibody

Dopamine-containing systems in the CNS

The patterns of afferent innervation of the core and shell in the “accumbens” part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold

J. comp. Neurol.

The current status of the dopamine hypothesis of schizophrenia

Neuropsychopharmacology

Molecular diversity of dopamine receptors

A. Rev. Pharmac. Toxic.

Is eye movement dysfunction a biological marker for schizophrenia? A methodological review

Psychol. Bull.

Linkage analysis of schizophrenia with gene dopamine receptor genes in nine pedigrees

Am. J. hum. Genet.

Association between schizophrenia and homozygosity at the dopamine D3 receptor gene

J. med. Genet.

Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease

J. neural Transm. (Gen. Sect.)

Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens

Eur. J. Neurosci.

Substantia nigra

Phenotypical characterization of neurons expressing the dopamine D₃ receptor in the rat brain

Association between schizophrenia and homozygosity at the dopamine D₃ receptor gene

Opposing roles for dopamine D₂ and D₃ receptors on neurotensin mRNA expression in nucleus accumbens